The α4β7 blockade with vedolizumab is effective in prevention of graft <i>vs</i>. host disease using a xenogeneic mouse model

Palaniyandi, Senthilnathan; Kumari, Reena; Strattan, Ethan; Huang, Timothy; Du, Jing; Hakim, Natalya; Kesler, Melissa

doi:10.1002/ajh.25678

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical improvement seen in our single patient demonstrates that vedolizumab may be effective in children with SRaGVHD. Given the unmet need for novel therapies to treat SRaGVHD in children, 10 prospective pediatric studies using vedolizumab seems to be a reasonable option to pursue.…”

Section: Figurementioning

confidence: 99%

Successful treatment of steroid‐refractory gastrointestinal acute graft‐versus‐host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient

Pai

Abu‐Arja

Auletta

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

LETTER TO THE EDITOR around D +224 she was diagnosed with pulmonary GVHD and therefore received photopheresis (biweekly) and ruxolitinb (5 mg twice daily). Ruxolitinb was discontinued due to lack of response and intolerance. She then received eight infusions of mesenchymal stromal cells (2 × 10 6 MSCs/kg) again with no response. On D +266 post-BMT, she commenced treatment intravenous vedolizumab (6 mg/kg: 200 mg) and received three doses on weeks 0, 2, and 6. She tolerated the infusions and experienced no side effects. She had a partial response on day 7 (stage one GI, grade II aGVHD) and complete response (grade 0 aGVHD) on day nine from the first and second dose of vedolizumab, respectively. Fecal calprotectin decreased from 1285 𝜇g/g (0-50 𝜇g/g) pre-vedolizumab to 295 𝜇g/g post-vedolizumab. The patient suffered no infectious complications. She is now 34 months post-BMT with no GI symptoms, gaining weight with a performance score of 90% and 99% donor chimerism in whole blood, CD3, and CD33 fractions. Her pulmonary GVHD responded to ibrutinib (started 23 months post-BMT). The clinical improvement seen in our single patient demonstrates that vedolizumab may be effective in children with SRaGVHD.Given the unmet need for novel therapies to treat SRaGVHD in children, 10 prospective pediatric studies using vedolizumab seems to be a reasonable option to pursue.

show abstract

Section: Figurementioning

confidence: 99%

Successful treatment of steroid‐refractory gastrointestinal acute graft‐versus‐host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient

Pai

Abu‐Arja

Auletta

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…44 Murine models have demonstrated decreased gut GVHD pathology and symptoms while promoting a survival benefit when vedolizumab was administered before donor T cell priming. 45 To date, there has been only 1 phase Ib dose-finding study reporting on the use of this agent in the setting of prevention (Table 4). 42 In a population of HLA matched or mismatched, unrelated or related donor HCT recipients, participants received intravenous vedolizumab (75 mg in 3 patients in the dosefinding phase and 300 mg in 21 patients in the expansion phase) on day À1, day +13, and day +42 in combination with tacrolimus and methotrexate.…”

Section: Vedolizumabmentioning

confidence: 99%

Acute Graft‐versus‐Host Disease: Emerging Insights and Updates into Detection, Prevention, and Treatment

DiMaggio

2020

Pharmacotherapy

View full text Add to dashboard Cite

Acute graft‐versus‐host disease remains a devastating complication following hematopoietic cell transplantation, resulting in increased morbidity and mortality. Vast research efforts continue to refine or develop new means of prediction, assessment, prevention, and treatment of this syndrome. Recent updates in acute graft‐versus‐host disease include more definitive guidance and definitions for its grading and diagnosis. Biomarker use is being incorporated into early stages following hematopoietic cell transplantation to aid in the detection and prediction of long‐term outcomes. New preventive strategies under investigation include the use of vedolizumab or tocilizumab as upfront prophylaxis. Finally, although steroids remain the backbone of therapy once treatment is warranted, the efficacy of several agents including vedolizumab, tocilizumab, ruxolitinib, and α1 antitrypsin are being evaluated as potential therapeutic options.

show abstract

The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model

Cited by 2 publications

References 10 publications

Successful treatment of steroid‐refractory gastrointestinal acute graft‐versus‐host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient

Successful treatment of steroid‐refractory gastrointestinal acute graft‐versus‐host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient

Acute Graft‐versus‐Host Disease: Emerging Insights and Updates into Detection, Prevention, and Treatment

Contact Info

Product

Resources

About